# NEKTAR THERAPEUTICS (NKTR)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/NKTR/

- Reporting holders: 4
- Reported value: $202.6M
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Two Seas Capital LP](https://holderbook.com/funds/1823138-two-seas-capital-lp/) | $202.6M | 3,345,978 | 2.3% | 4 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $15.6K | 257 | 0.0% | 3 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $1.8K | 30 | 0.0% | 2 |
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $303 | 5 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 4 | $202.6M |
| Q2 2026 | 246 | $2.8B |
| Q1 2026 | 217 | $2.1B |
| Q4 2025 | 182 | $796.2M |
| Q3 2025 | 156 | $943.9M |
| Q2 2025 | 113 | $265.8M |
| Q1 2025 | 159 | $85.4M |
| Q4 2024 | 146 | $124.7M |
| Q3 2024 | 139 | $184.3M |
| Q2 2024 | 133 | $173.6M |
| Q1 2024 | 120 | $106.3M |
| Q4 2023 | 121 | $67.7M |